Episealer® presentation at the 20th ESSKA Congress, held on April 27-29 in Paris, France
Episurf Medical (NASDAQ: EPIS B) will attend the 20th ESSKA Congress, held on April 27-29 in Paris, France. At the congress, a scientific presentation, focusing on the company’s Episealer® knee and Episealer® Talus technologies will be held by Prof. Niek van Dijk and Prof. Peter Verdonk. The presentation, entitled “Personalised joint resurfacing – treatment of (osteo-)chondral lesions in the knee and ankle”, will be held on Wednesday April 27 at 13.00.
ESSKA is the European Society of Sports Traumatology, Knee Surgery and Arthroscopy. Their goal is to bring together orthopaedic surgeons, clinicians, and scientists in Europe, along with their various societies. The ESSKA Congress is held every two years.
"The ESSKA Congress 2022 is probably our biggest and most important meeting during 2022. We are delighted to be able to meet our customers in this setting again, and we could not have asked for a better way to present the Episealer® technology, than through the presentation given by Prof. van Dijk and Prof. Verdonk”, comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: